Fortune India 500 2025 edition
Rank#229- Total income
- ₹11,814 Cr
- Profit
- ₹1,911 Cr
Last year #220
Torrent Pharmaceuticals Ltd - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
Active Listed - NSE: TORNTPHARM · BSE: 500420 Public Limited Company pharma Fortune India 500 · #229 Nifty 500
Revenue · FY 2025-26
₹19,274 Cr
▲ 67.4% YoY
EBITDA · FY 2025-26
₹4,469.71 Cr
▲ 20.9% YoY
Net profit · FY 2025-26
₹2,191.62 Cr
▲ 14.4% YoY
Net worth · FY 2025-26
₹8,388.43 Cr
Latest filings
Authorised capital
₹235 Cr
Registered with MCA
Paid-up capital
₹169.22 Cr
Issued & subscribed
Open charges
₹13,352 Cr
Satisfied ₹10,034 Cr
Company age
54 yrs
Est. 1972
About Torrent Pharmaceuticals Ltd
Data last updated:
Torrent Pharmaceuticals Ltd is a public limited company based in Ahmedabad, Gujarat, India, a subsidiary of Torrent Investments Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 July 1972 and has been in existence for over 54 years.
Torrent Pharmaceuticals is ranked #229 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Samir Mehta and family are #10 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1972PLC002126. Its GSTIN is 24AAACT5456A1ZR (Gujarat). The company holds 40 GST registrations, of which 25 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500420 and NSE: TORNTPHARM.
The company has an authorised share capital of ₹235 Cr and a paid-up capital of ₹169.22 Cr. It was formerly known as Torrent Laboratories Private Limited and Torrent Pharmaceuticals Pvt Ltd. It is led by directors including Samir Uttamlal Mehta (Managing Director) and Aman Samir Mehta (Managing Director).
Its last annual general meeting (AGM) was held on 28 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Avirat, Thaltej Shilaj Road Ahmedabad, Gujarat, India – 380059.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹19,274 Cr, a growth of 67.4% compared to the previous year. For the same year it recorded a net profit of ₹2,191.62 Cr (net margin 11.4%) and EBITDA of ₹4,469.71 Cr (EBITDA margin 23.2%). The net worth stands at ₹8,388.43 Cr (up 10.5% YoY). Total assets are valued at ₹33,483 Cr (up 196.1% YoY).
The company has about 15,615 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Tedibar and Torrent Pharma. As per MCA filings, the company has open charges of ₹13,352 Cr and satisfied charges of ₹10,034 Cr on record. Court records list 472 cases involving the company, including 219 filed by the company and 253 filed against it; 138 cases are pending. The company has 50 deals on record (37 market trades, 13 secondary share transfers); the latest was in January 2025. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Hetero Labs Limited with revenue of ₹16,537 Cr. The company has 12 MSME Form 1 returns on record between 2018 and 2024, listing 185 overdue payments to 76 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website torrentpharma.com.
Company details
CIN L24230GJ1972PLC002126
Registration Number 002126
Incorporation Date 15 July 1972
ROC Ahmedabad
Listing Status Listed - Listed on NSE (TORNTPHARM); Listed on BSE (500420)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2026
Parent Company Torrent Investments Private Limited
Compliance Status Active Compliant
Name history
Torrent Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Torrent Laboratories Private Limited, and Torrent Pharmaceuticals Pvt Ltd. The current legal name is Torrent Pharmaceuticals Ltd.
| Company Name | Status |
|---|---|
| Torrent Pharmaceuticals Ltd | Current |
| Torrent Laboratories Private Limited | Previous |
| Torrent Pharmaceuticals Pvt Ltd | Previous |
Key People
Samir Uttamlal Mehta Managing Director Aman Samir Mehta Managing Director Nayantara Bali Director Recognitions & Rankings of Torrent Pharmaceuticals
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#54- Valuation
- ₹1,12,910 Cr
2023 #68 2022 #69 2021 #89
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #10 Samir Mehta & family ₹1,89,400 Cr
Stock market indices
Nifty 500 BSE 500
Contact details
Torrent Pharmaceuticals Ltd's registered office is in Ahmedabad, Gujarat. Its website is torrentpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressAvirat, Thaltej Shilaj Road Ahmedabad, Gujarat, India – 380059
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Torrent Pharmaceuticals Ltd, buy the company report.
Comprehensive company report
Torrent Pharmaceuticals Ltd - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Torrent Pharmaceuticals operates two associated brands: Tedibar and Torrent Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers gentle, moisturizing baby bathing bars and washes for sensitive skin care. | tedibar.com | |
| Formulations, APIs, drug discovery, marketing, and sales services are provided. | torrentpharma.com |
Business activity
The main business activity of Torrent Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Torrent Pharmaceuticals Ltd, buy the company report.
Financials of Torrent Pharmaceuticals Ltd
FY 2025-26 filings availableTorrent Pharmaceuticals Ltd reported revenue of ₹19,274 Cr (up 67.4% YoY) for FY 2025-26.
Revenue · FY 2025-26
₹19,274 Cr ▲ 67.4%
Profit · FY 2025-26
₹2,191.62 Cr ▲ 14.4%
Computed EBITDA · FY 2025-26
₹4,469.71 Cr ▲ 20.9%
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹19,274 Cr | ₹11,516 Cr | ₹10,728 Cr | ₹9,620.15 Cr | ₹8,508.04 Cr | ₹8,004.57 Cr | ₹7,939.31 Cr |
| Other Income | -₹93.58 Cr | ₹23.27 Cr | ₹146.29 Cr | ₹45.14 Cr | ₹196.56 Cr | ₹56.91 Cr | ₹121.3 Cr |
| Cost of Materials Consumed | ₹3,376.77 Cr | ₹3,050.82 Cr | ₹2,841.22 Cr | ₹2,569 Cr | ₹2,368.15 Cr | ₹2,425.66 Cr | ₹2,300.05 Cr |
| Employee Benefit Expense | ₹2,670.85 Cr | ₹2,203.37 Cr | ₹1,984.4 Cr | ₹1,677.69 Cr | ₹1,526.45 Cr | ₹1,439.62 Cr | ₹1,429.04 Cr |
| Finance Costs | ₹385.07 Cr | ₹252.31 Cr | ₹353.56 Cr | ₹333.44 Cr | ₹255.06 Cr | ₹352.94 Cr | ₹450.71 Cr |
| Depreciation & Amortisation | ₹1,118.87 Cr | ₹794.93 Cr | ₹808.27 Cr | ₹706.59 Cr | ₹662.16 Cr | ₹657.79 Cr | ₹654.38 Cr |
| Other Expenses | ₹7,456.09 Cr | ₹1,781.96 Cr | ₹1,674.65 Cr | ₹1,502.7 Cr | ₹1,278.57 Cr | ₹1,155.1 Cr | ₹1,317.15 Cr |
| Total Expenses | ₹14,805 Cr | ₹7,819.31 Cr | ₹7,360.19 Cr | ₹6,778.1 Cr | ₹6,561.47 Cr | ₹5,524.49 Cr | ₹5,768.95 Cr |
| Profit Before Tax | ₹2,872.19 Cr | ₹2,672.81 Cr | ₹2,352.11 Cr | ₹1,847.16 Cr | ₹1,225.91 Cr | ₹1,526.26 Cr | ₹1,186.57 Cr |
| Total Tax Expense | ₹734.01 Cr | ₹761.56 Cr | ₹695.73 Cr | ₹601.93 Cr | ₹448.73 Cr | ₹274.38 Cr | ₹161.85 Cr |
| Net Profit | ₹2,191.62 Cr | ₹1,915.63 Cr | ₹1,581.26 Cr | ₹1,217.5 Cr | ₹1,076.48 Cr | ₹1,239.71 Cr | ₹1,001.92 Cr |
| EBITDA (computed) | ₹4,469.71 Cr | ₹3,696.78 Cr | ₹3,367.65 Cr | ₹2,842.05 Cr | ₹1,946.57 Cr | ₹2,480.08 Cr | ₹2,170.36 Cr |
| Basic EPS | ₹63.92 | ₹56.47 | ₹48.94 | ₹36.79 | ₹45.92 | ₹73.97 | ₹60.55 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹33,483 Cr | ₹11,309 Cr | ₹11,333 Cr | ₹11,982 Cr | ₹10,401 Cr | ₹11,094 Cr | ₹11,065 Cr |
| Current Assets | ₹8,526.15 Cr | ₹5,510.36 Cr | ₹5,470.44 Cr | ₹5,157.63 Cr | ₹4,981.01 Cr | ₹5,382.45 Cr | ₹4,979.04 Cr |
| Property, Plant & Equipment | ₹33,191 Cr | ₹7,946.9 Cr | ₹8,138.11 Cr | ₹8,121.45 Cr | ₹6,422.65 Cr | ₹7,064.63 Cr | ₹7,533.12 Cr |
| Inventories | ₹3,138.19 Cr | ₹2,541.25 Cr | ₹2,279.07 Cr | ₹2,229.64 Cr | ₹2,462.32 Cr | ₹2,681.2 Cr | ₹2,148.22 Cr |
| Trade Receivables | ₹3,030.86 Cr | ₹1,866.45 Cr | ₹1,844.3 Cr | ₹1,943.82 Cr | ₹1,632.48 Cr | ₹1,523.37 Cr | ₹1,649.34 Cr |
| Cash & Equivalents | ₹1,165.2 Cr | ₹579.46 Cr | ₹839.04 Cr | ₹571.46 Cr | ₹403.41 Cr | ₹603.5 Cr | ₹666.65 Cr |
| Equity (Net Worth) | ₹8,388.43 Cr | ₹7,590.69 Cr | ₹6,856.15 Cr | ₹6,198.07 Cr | ₹5,952.95 Cr | ₹5,837.17 Cr | ₹4,823.22 Cr |
| Equity Share Capital | ₹169.23 Cr | ₹169.23 Cr | ₹169.23 Cr | ₹169.23 Cr | ₹84.62 Cr | ₹84.62 Cr | ₹84.62 Cr |
| Total Debt (computed) | ₹15,026 Cr | ₹3,202.32 Cr | ₹4,021.94 Cr | ₹5,368.56 Cr | ₹4,069.65 Cr | ₹4,874.13 Cr | ₹5,784.35 Cr |
| Current Liabilities | ₹5,159.07 Cr | ₹2,852.48 Cr | ₹3,071.55 Cr | ₹2,627.89 Cr | ₹2,505.48 Cr | ₹2,980.76 Cr | ₹2,945.03 Cr |
| Total Liabilities | ₹33,483 Cr | ₹11,309 Cr | ₹11,333 Cr | ₹11,982 Cr | ₹10,401 Cr | ₹11,094 Cr | ₹11,065 Cr |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ₹3,022.71 Cr | ₹2,585.11 Cr | ₹3,266.08 Cr | ₹2,368.13 Cr | ₹1,802.99 Cr | ₹2,005.35 Cr | ₹1,392.91 Cr |
| Investing Cash Flow | -₹12,630 Cr | -₹548.78 Cr | -₹159.83 Cr | -₹2,335.36 Cr | -₹196.1 Cr | -₹443.82 Cr | ₹229.19 Cr |
| Financing Cash Flow | ₹10,151 Cr | -₹2,297.99 Cr | -₹2,779.64 Cr | ₹77.36 Cr | -₹1,781.05 Cr | -₹1,650.79 Cr | -₹1,549.04 Cr |
| Net Change in Cash | ₹543.72 Cr | -₹261.66 Cr | ₹326.61 Cr | ₹110.13 Cr | -₹174.16 Cr | -₹89.26 Cr | ₹73.06 Cr |
| Metrics | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹4,979 Cr | ₹4,921 Cr | ₹4,197 Cr | ₹3,303 Cr | ₹3,302 Cr | ₹3,178 Cr | ₹2,959 Cr | ₹2,809 Cr | ₹2,889 Cr | ₹2,859 Cr |
| Other Income | -₹10 Cr | -₹12 Cr | -₹17 Cr | -₹13 Cr | -₹27 Cr | -₹37 Cr | -₹18 Cr | ₹33 Cr | -₹16 Cr | ₹24 Cr |
| Total Income | ₹4,979 Cr | ₹4,921 Cr | ₹4,197 Cr | ₹3,303 Cr | ₹3,302 Cr | ₹3,178 Cr | ₹2,959 Cr | ₹2,809 Cr | ₹2,889 Cr | ₹2,859 Cr |
| Finance Costs | ₹300 Cr | ₹305 Cr | ₹236 Cr | ₹45 Cr | ₹48 Cr | ₹56 Cr | ₹56 Cr | ₹57 Cr | ₹64 Cr | ₹75 Cr |
| Depreciation & Amortisation | ₹609 Cr | ₹593 Cr | ₹508 Cr | ₹206 Cr | ₹204 Cr | ₹201 Cr | ₹201 Cr | ₹199 Cr | ₹198 Cr | ₹197 Cr |
| Profit Before Tax | ₹737 Cr | ₹733 Cr | ₹529 Cr | ₹814 Cr | ₹791 Cr | ₹738 Cr | ₹665 Cr | ₹691 Cr | ₹661 Cr | ₹656 Cr |
| Total Tax Expense | ₹203 Cr | ₹167 Cr | ₹165 Cr | ₹179 Cr | ₹200 Cr | ₹190 Cr | ₹167 Cr | ₹188 Cr | ₹208 Cr | ₹199 Cr |
| Net Profit | ₹534 Cr | ₹566 Cr | ₹364 Cr | ₹635 Cr | ₹591 Cr | ₹548 Cr | ₹498 Cr | ₹503 Cr | ₹453 Cr | ₹457 Cr |
| EBITDA (computed) | ₹1,656 Cr | ₹1,643 Cr | ₹1,290 Cr | ₹1,078 Cr | ₹1,070 Cr | ₹1,032 Cr | ₹940 Cr | ₹914 Cr | ₹939 Cr | ₹904 Cr |
| Basic EPS | ₹14.05 | ₹14.87 | ₹11.51 | ₹18.77 | ₹17.45 | ₹16.19 | ₹14.71 | ₹14.88 | ₹13.37 | ₹13.51 |
Latest 10 quarters shown.
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹10,713 Cr | ₹9,683.43 Cr | ₹8,532.9 Cr | ₹7,695.2 Cr | ₹6,742.32 Cr | ₹6,450.57 Cr | ₹6,168.44 Cr |
| Other Income | ₹17.92 Cr | ₹31.5 Cr | ₹91.36 Cr | ₹81.88 Cr | ₹204.17 Cr | ₹118.34 Cr | ₹236.93 Cr |
| Cost of Materials Consumed | ₹2,334.64 Cr | ₹2,249.84 Cr | ₹2,200.39 Cr | ₹2,010.98 Cr | ₹1,925.84 Cr | ₹1,819.81 Cr | ₹1,694.28 Cr |
| Employee Benefit Expense | ₹1,879.4 Cr | ₹1,636.45 Cr | ₹1,450.67 Cr | ₹1,251.22 Cr | ₹1,097.93 Cr | ₹1,097.12 Cr | ₹1,061.76 Cr |
| Finance Costs | ₹340.96 Cr | ₹213.4 Cr | ₹303.04 Cr | ₹297.68 Cr | ₹236.29 Cr | ₹334.12 Cr | ₹430.49 Cr |
| Depreciation & Amortisation | ₹763.54 Cr | ₹759.48 Cr | ₹761.05 Cr | ₹672.34 Cr | ₹602.43 Cr | ₹609.84 Cr | ₹606.66 Cr |
| Other Expenses | ₹1,558.61 Cr | ₹1,397.82 Cr | ₹1,254.38 Cr | ₹1,138.57 Cr | ₹954.66 Cr | ₹851.08 Cr | ₹918.63 Cr |
| Total Expenses | ₹6,729.95 Cr | ₹6,131.87 Cr | ₹5,643.6 Cr | ₹5,230.04 Cr | ₹4,641.56 Cr | ₹4,258.84 Cr | ₹4,251.45 Cr |
| Profit Before Tax | ₹2,896.61 Cr | ₹2,610.18 Cr | ₹1,916.57 Cr | ₹1,577.02 Cr | ₹1,466.21 Cr | ₹1,366.11 Cr | ₹1,116.77 Cr |
| Total Tax Expense | ₹705.02 Cr | ₹722.12 Cr | ₹559.49 Cr | ₹525.63 Cr | ₹474.76 Cr | ₹228.26 Cr | ₹178.26 Cr |
| Net Profit | ₹2,212.52 Cr | ₹1,892.26 Cr | ₹1,342.2 Cr | ₹1,023.42 Cr | ₹984.59 Cr | ₹1,125.1 Cr | ₹914.33 Cr |
| EBITDA (computed) | ₹3,983.19 Cr | ₹3,551.56 Cr | ₹2,889.3 Cr | ₹2,465.16 Cr | ₹2,100.76 Cr | ₹2,191.73 Cr | ₹1,916.99 Cr |
| Basic EPS | ₹64.75 | ₹55.78 | ₹40.10 | ₹31.06 | ₹58.58 | ₹67.23 | ₹55.45 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹23,182 Cr | ₹10,574 Cr | ₹10,465 Cr | ₹11,298 Cr | ₹9,910.76 Cr | ₹10,635 Cr | ₹10,667 Cr |
| Current Assets | ₹4,764.2 Cr | ₹4,236.59 Cr | ₹3,600.02 Cr | ₹3,770.99 Cr | ₹3,749.42 Cr | ₹4,002.83 Cr | ₹3,819.24 Cr |
| Property, Plant & Equipment | ₹7,370.16 Cr | ₹7,554.04 Cr | ₹7,985.92 Cr | ₹7,971.85 Cr | ₹6,251.25 Cr | ₹6,741.24 Cr | ₹7,197.5 Cr |
| Inventories | ₹1,526.23 Cr | ₹1,560.83 Cr | ₹1,565.59 Cr | ₹1,602.23 Cr | ₹1,797.11 Cr | ₹1,911.74 Cr | ₹1,507.76 Cr |
| Trade Receivables | ₹2,641.05 Cr | ₹2,170.79 Cr | ₹1,571.94 Cr | ₹1,729.44 Cr | ₹1,541.35 Cr | ₹1,544.26 Cr | ₹1,508.94 Cr |
| Cash & Equivalents | ₹82.98 Cr | ₹109.74 Cr | ₹108.76 Cr | ₹147.61 Cr | ₹69.46 Cr | ₹66.42 Cr | ₹390.95 Cr |
| Equity (Net Worth) | ₹8,452.17 Cr | ₹7,592.5 Cr | ₹6,828.76 Cr | ₹6,455.96 Cr | ₹6,345.42 Cr | ₹6,030.1 Cr | ₹5,120.97 Cr |
| Equity Share Capital | ₹169.23 Cr | ₹169.23 Cr | ₹169.23 Cr | ₹169.23 Cr | ₹84.62 Cr | ₹84.62 Cr | ₹84.62 Cr |
| Total Debt (computed) | ₹14,277 Cr | ₹2,629.02 Cr | ₹3,344.2 Cr | ₹4,575.47 Cr | ₹3,347.51 Cr | ₹4,404.14 Cr | ₹5,294.34 Cr |
| Current Liabilities | ₹1,867.46 Cr | ₹1,439.72 Cr | ₹1,255.47 Cr | ₹1,172.33 Cr | ₹1,048.24 Cr | ₹1,126.31 Cr | ₹1,217.59 Cr |
| Total Liabilities | ₹23,182 Cr | ₹10,574 Cr | ₹10,465 Cr | ₹11,298 Cr | ₹9,910.76 Cr | ₹10,635 Cr | ₹10,667 Cr |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ₹2,730.83 Cr | ₹2,574.5 Cr | ₹2,893.1 Cr | ₹2,265.41 Cr | ₹2,140.1 Cr | ₹1,572.89 Cr | ₹1,579.9 Cr |
| Investing Cash Flow | -₹12,990 Cr | -₹470.09 Cr | -₹296.07 Cr | -₹2,325.75 Cr | -₹159.7 Cr | -₹316.28 Cr | ₹269.43 Cr |
| Financing Cash Flow | ₹10,225 Cr | -₹2,104.46 Cr | -₹2,577.57 Cr | ₹80.74 Cr | -₹1,977.27 Cr | -₹1,581.2 Cr | -₹1,555.48 Cr |
| Net Change in Cash | -₹34.14 Cr | -₹5 Lakh | ₹19.46 Cr | ₹20.4 Cr | ₹3.13 Cr | -₹324.59 Cr | ₹293.85 Cr |
| Metrics | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹4,145 Cr | ₹4,158 Cr | ₹3,445 Cr | ₹2,599 Cr | ₹2,762 Cr | ₹2,616 Cr | ₹2,433 Cr | ₹2,377 Cr | ₹2,434 Cr | ₹2,438 Cr |
| Other Income | -₹11 Cr | -₹21 Cr | -₹30 Cr | -₹8 Cr | -₹27 Cr | -₹5 Cr | ₹15 Cr | ₹3 Cr | -₹7 Cr | ₹21 Cr |
| Total Income | ₹4,145 Cr | ₹4,158 Cr | ₹3,445 Cr | ₹2,599 Cr | ₹2,762 Cr | ₹2,616 Cr | ₹2,433 Cr | ₹2,377 Cr | ₹2,434 Cr | ₹2,438 Cr |
| Finance Costs | ₹287 Cr | ₹293 Cr | ₹226 Cr | ₹34 Cr | ₹37 Cr | ₹45 Cr | ₹47 Cr | ₹48 Cr | ₹54 Cr | ₹64 Cr |
| Depreciation & Amortisation | ₹587 Cr | ₹575 Cr | ₹490 Cr | ₹191 Cr | ₹189 Cr | ₹187 Cr | ₹190 Cr | ₹191 Cr | ₹190 Cr | ₹189 Cr |
| Total Expenses | ₹2,584 Cr | ₹2,606 Cr | ₹2,283 Cr | ₹1,609 Cr | ₹1,703 Cr | ₹1,637 Cr | ₹1,589 Cr | ₹1,490 Cr | ₹1,513 Cr | ₹1,539 Cr |
| Profit Before Tax | ₹676 Cr | ₹663 Cr | ₹416 Cr | ₹757 Cr | ₹806 Cr | ₹742 Cr | ₹622 Cr | ₹651 Cr | ₹670 Cr | ₹667 Cr |
| Total Tax Expense | ₹178 Cr | ₹171 Cr | ₹107 Cr | ₹180 Cr | ₹209 Cr | ₹191 Cr | ₹148 Cr | ₹166 Cr | ₹210 Cr | ₹198 Cr |
| EBITDA (computed) | ₹1,561 Cr | ₹1,552 Cr | ₹1,162 Cr | ₹990 Cr | ₹1,059 Cr | ₹979 Cr | ₹844 Cr | ₹887 Cr | ₹921 Cr | ₹899 Cr |
Latest 10 quarters shown.
To see the full year-wise statements and ratios of Torrent Pharmaceuticals Ltd, buy the company report.
Board of directors of Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals has 7 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Samir Uttamlal Mehta | Managing Director | 01 Aug 2010 | 16 Years 2 Months | Current |
| Nayantara Bali Also directs: Marico Limited | Director | 07 Mar 2019 | 7 Years 7 Months | Current |
| Manish Mahendra Choksi | Director | 29 Jul 2022 | 4 Years 2 Months | Current |
| Ameera Sushil Shah | Director | 02 Aug 2018 | 8 Years 2 Months | Current |
| Aman Samir Mehta Also directs: Radiant Urja LLP, Torrent Investments Limited, Torrent Gujarat Titans Private Limited and 2 more | Managing Director | 31 Jul 2025 | 1 Years 2 Months | Current |
| Jinal Sudhirbhai Mehta | Director | 24 May 2024 | 2 Years 5 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Torrent Pharmaceuticals Ltd is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals Ltdthis company | ₹19,274 Cr (FY 2026) | ₹2,191.62 Cr | 11.4% | 67.4% | 15,615 | Ahmedabad, Gujarat, India |
| Hetero Labs Limited | ₹16,537 Cr (FY 2025) | 13.0% | Hyderabad, Telangana, India | |||
| Biocon Limited | ₹16,470 Cr (FY 2025) | 5.0% | Bengaluru, Karnataka, India | |||
| Alkem Laboratories Limited | ₹13,458 Cr (FY 2025) | 4.0% | Mumbai, Maharashtra, India | |||
| Glenmark Pharmaceuticals Limited | ₹13,435 Cr (FY 2025) | 6.0% | Mumbai, Maharashtra, India | |||
| Serum Institute of India Private Limited | ₹10,854 Cr (FY 2025) | -2.0% | Pune, Maharashtra, India | |||
| Macleods Pharmaceuticals Ltd | ₹9,671.68 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Ipca Laboratories Limited | ₹9,032.39 Cr (FY 2025) | 15.0% | Mumbai, Maharashtra, India | |||
| Abbott Healthcare Private Limited | ₹8,811.32 Cr (FY 2025) | 3.0% | Mumbai, Maharashtra, India | |||
| Emcure Pharmaceuticals Limited | ₹7,963.26 Cr (FY 2025) | 19.0% | Pune, Maharashtra, India |
To see the full peer comparison of Torrent Pharmaceuticals Ltd, buy the company report.
Auditor
Torrent Pharmaceuticals Ltd is audited by B S R & Co. LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| B S R & Co. LLP | FY 2024 | 101248W/W-100022 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 68.30%, foreign institutional investors hold 15.40%, domestic institutional investors hold 9.90% and retail and other public shareholders hold 6.40%.
Sep 2026
QUARTER
68.30% Promoters
9.90% DII (Domestic Institutional)
15.40% FII (Foreign Institutional)
6.40% Retail & Others
Promoter holding - history
Now 68.30% · Sep 2026High 68.30% · Dec 2025Low 68.30% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% |
| Public | 31.70% | 31.70% | 31.70% | 31.70% |
Charges & borrowings
Open charges
₹13,352 Cr
Satisfied charges
₹10,034 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Apr 2026 | 101282150 | Hdfc Bank Limited | ₹266.88 Cr | Open | |
| 08 Apr 2026 | 101283754 | The Hongkong and Shanghai Banking Corporation Limited | ₹300 Cr | Open | |
| 12 Jan 2026 | 101230130 | Idbi Trusteeship Services Limited | ₹10,990 Cr | Open | |
| 07 Feb 2023 | 100688815 | Idbi Trusteeship Services Limited | ₹400 Cr | Open | |
| 02 Apr 2022 | 100561525 | Hdfc Bank Limited | ₹450 Cr | Open |
To see the full charge records of Torrent Pharmaceuticals Ltd, buy the company report.
Total charge records: 65 View all charges
Deals & funding
Torrent Pharmaceuticals Ltd has 50 deals on record (37 market trades, 13 secondary share transfers); the latest was in January 2025.
Total deals
50
Market trades
37
Secondary share transfers
13
Deals on record (5 of 50)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2024 | Market trade | ₹3,086.37 Cr | Seller: Torrent Investments Limited |
| Jul 2017 | Secondary share transfer | Undisclosed | Buyer: Torrent Investments Limited , Hdfc Trustee Co Ltd Hdfc Multiple Yield Fund-Plan 2005, Birla Sun Life Trustee Company Private Limited A/C Birla Sun Life Balanced 95 Fund Seller: Sudhir U Mehta HUF, Others-Torrent Pharmaceuticals Limited, 2 individuals |
| Jul 2009 | Secondary share transfer | Undisclosed | Buyer: Torrent Investments Limited Seller: Others-Torrent Pharmaceuticals Limited, Franklin Templeton Mutual Fund A/C Franklin India Prima Fund |
| Nov 2007 | Market trade | ₹19 Cr | Buyer: Icici Securities Primary Dealership Limited Seller: Templeton Mutual Fund Ac Franklin India Prima Plus Ac 4616 |
| Oct 2007 | Market trade | ₹96.72 Cr | Buyer: Icici Securities Primary Dealership Limited Seller: Mavi Investment |
To see the full deal history of Torrent Pharmaceuticals Ltd, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Torrent Pharmaceuticals Ltd has 472 court cases on record: 219 filed by Torrent Pharmaceuticals, 253 filed against it. 138 cases are pending and 334 are disposed.
Total cases
472
Filed by the company
219
Filed against the company
253
Pending
138
Disposed
334
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 231 | 144 | 76 |
| District courts | 215 | 85 | 55 |
| Supreme Court | 20 | 19 | 2 |
| NCLAT | 5 | 5 | 5 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 472)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Commercial suit | Filed by the company against N.U Indian Herbal Research Laboratory P. Ltd. | Pending |
| High Court of Delhi | Commercial suit | Filed by the company against I-Next Pharmaceutical P. Ltd. & Anr. | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed by the company against Eris Life Sciences Pvt Limited and 2 others | Pending |
| High Court, GUJARAT | Special civil application | Filed by the company against Ahmedabad and 1 other | Pending |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed by the company against Mervin Healthcare Pvt. Ltd. | Disposed |
To see the full case history of Torrent Pharmaceuticals Ltd, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Torrent Pharmaceuticals Ltd was last rated by Icra on 30 Aug 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 30 Aug 2021 |
To see the full credit ratings and regulatory alerts of Torrent Pharmaceuticals Ltd, buy the company report.
MSME payment delays
Torrent Pharmaceuticals Ltd has 12 MSME Form 1 returns on record between 2018 and 2024, listing 185 overdue payments to 76 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 76)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| June Enterprises Private Limited | |||
| Raj Barcode Systems Private Limited | |||
| Satya Packaging | |||
| Vishruta Packaging Private Limited |
To see the full MSME payment records of Torrent Pharmaceuticals Ltd, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Torrent Pharmaceuticals has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
Torrent Pharmaceuticals Ltd has a workforce of 15,615 employees on its EPFO records as of Mar 10, 2025, across 8 active EPFO establishments.
Employee count
15,615
Active EPFO establishments
8
Employee growth
6.46%
GST
Torrent Pharmaceuticals has 40 GST registrations: 25 active and 15 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
40
Active
25
Cancelled / inactive
15
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACT5456A1ZR | Gujarat | Active | 01 Jul 2017 |
| 24AAACT5456A2ZQ | Gujarat | Active | 01 Jul 2017 |
| 24AAACT5456A3ZP | Gujarat | Active | 19 Jul 2017 |
| 02AAACT5456A1ZX | Himachal Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Torrent Pharmaceuticals Ltd, buy the company report.
Recent activity
Torrent Pharmaceuticals Ltd has 50 board changes on record since 1982: 29 appointments and 21 cessations. The latest: Aman Samir Mehta was appointed as Managing Director on 31 Jul 2025.
Charges
A charge registered on 05 Apr 2013 via Charge ID 10421600 with Bnp Paribas was fully satisfied on 11 Jun 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 266.88 Cr with Charge ID 101282150 was registered on 08 Apr 2026.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 300.00 Cr with Charge ID 101283754 was registered on 08 Apr 2026.
Charges
A charge with Idbi Trusteeship Services Limited of Rs. 400.00 Cr registered on 07 Feb 2023 with Charge ID 100688815 was modified on 08 Apr 2026.
Filing
Torrent Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge registered on 12 Oct 2018 via Charge ID 100212700 with Idbi Trusteeship Services Limited was fully satisfied on 05 Feb 2026.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 10,990.00 Cr with Charge ID 101230130 was registered on 12 Jan 2026.
Charges
A charge registered on 16 Mar 1988 via Charge ID 90314072 with State Bank Of Inida was fully satisfied on 09 Jan 2026.
Charges
A charge registered on 05 May 2005 via Charge ID 90103831 with Citibank N.A. was fully satisfied on 08 Jan 2026.
Charges
A charge registered on 13 Mar 2018 via Charge ID 100201579 with Idbi Trusteeship Services Limited was fully satisfied on 12 Dec 2025.
Charges
A charge registered on 24 Feb 2023 via Charge ID 100683495 with Hdfc Bank Limited was fully satisfied on 31 Oct 2025.
Charges
A charge registered on 26 Apr 2018 via Charge ID 100173917 with Idbi Trusteeship Services Limited was fully satisfied on 01 Oct 2025.
201 earlier events are in the company report.
News
TORNTPHARM: Rs. 27.78 Crores BSE Block Trade; for ~ 60,000 Shares, at Rs. 4630.00
Torrent Pharma: Kotak Institutional Equities on Torrent Pharma Upgrades to Buy, Target Price ₹5,665; Q2 was in line, with strong double-digit base-business growth offset by slower JB Pharma, Germany and higher R&D costs. JB cost synergies reached ₹1.2bn in H1, ahead of schedule, with revenue synergies expected from Q1FY28; forecasts 19% FY26–29 EBITDA CAGR.
Torrent Pharma: HSBC on Torrent Pharma Maintains Buy, Target Price ₹5,700; base India sales excluding JB Pharma rose 20% YoY, while JB performance was affected by post-merger integration. Branded-generics growth should support margin expansion, and recovery in JB Pharma's portfolio is the next catalyst.
Torrent Pharma: Citi on Torrent Pharma Maintains Buy, Target Price ₹5,860; Q2 was in line, with strong India and Brazil performance offset by temporary JB integration and delayed international deliveries. Management expects gradual JB recovery and improving H2 India growth; around half of the ₹4.5bn synergies are expected in FY27, with the balance in FY28.
Torrent Pharma: Jefferies on Torrent Pharma Maintains Buy, Target Price ₹5,900; India base business grew 20% YoY and Brazil delivered 21% constant-currency growth, while US growth remained steady. JB integration is ahead of schedule, with half of cost synergies achieved and revenue synergies expected to support next year's growth.
Torrent Pharma: Nomura on Torrent Pharma Maintains Neutral, Target Price ₹5,030; Q2 headline performance slightly missed expectations, but core business remained strong. The company now expects ₹4.5bn of JB Pharma acquisition synergies over two years instead of three, with margins expected to improve slightly in H2FY27 as operations stabilise.
From our blog
Frequently asked questions
Torrent Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 July 1972 (54+ years old) and is registered under CIN L24230GJ1972PLC002126. Listed on BSE: 500420 and NSE: TORNTPHARM.
Torrent Pharmaceuticals reported revenue of ₹19,274 Cr for FY 2025-26 (up 67.4% YoY) based on consolidated financials.
Torrent Pharmaceuticals has 7 current directors:
- Samir Uttamlal Mehta - Managing Director
- Aman Samir Mehta - Managing Director
- Nayantara Bali - Director
- Manish Mahendra Choksi - Director
- Ameera Sushil Shah - Director
- Jinal Sudhirbhai Mehta - Director
- Nikhil Khattau Nirvan - Director
The latest financial statements of Torrent Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 28 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Torrent Pharmaceuticals is 24AAACT5456A1ZR, registered in Gujarat. The company has 40 GST registrations in all, of which 25 are active and 15 are cancelled or inactive. Other active GSTINs include 24AAACT5456A2ZQ (Gujarat), 24AAACT5456A3ZP (Gujarat), 02AAACT5456A1ZX (Himachal Pradesh).
The CIN (Corporate Identification Number) of Torrent Pharmaceuticals is L24230GJ1972PLC002126. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Torrent Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 500420) and NSE (symbol: TORNTPHARM).
Torrent Pharmaceuticals has 472 court cases on record: 219 filed by the company and 253 filed against it. 138 are pending. Most are in the high courts.
Torrent Pharmaceuticals was incorporated on 15 July 1972, making it 54+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Torrent Pharmaceuticals has 50 deals on record (37 market trades, 13 secondary share transfers); the latest was in January 2025.
The peers of Torrent Pharmaceuticals by revenue are Hetero Labs Limited, Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Serum Institute of India Private Limited and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Aman Samir Mehta was appointed as Managing Director on 31 Jul 2025. Maurice Antoine Rene Chagnaud ceased to be Director on 10 May 2025. Jinesh Dushyant Shah ceased to be Director on 23 Jul 2024. Torrent Pharmaceuticals has 50 board changes on record in total.